Motoji Kogushi

The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease

Motoji Kogushi, Daniela Dastros-Pitei, Marcus Flather et al. · Thrombosis and Haemostasis · 2009 · 83 citations

Antibody to Thrombin Receptor Inhibits Neointimal Smooth Muscle Cell Accumulation Without Causing Inhibition of Platelet Aggregation or Altering Hemostatic Parameters After Angioplasty in Rat

Masahiro Takada, Hiroshi Tanaka, Toshie Yamada et al. · Circulation Research · 1998 · 51 citations · Full text

Sfflrnpsedtfeqf Peptide, Immunology, Immunotherapy +19

The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs

Motoji Kogushi, Toshiyuki Matsuoka, Tsutomu Kawata et al. · European Journal of Pharmacology · 2011 · 47 citations

Inflammation, Thrombosis, Cardiovascular Disease +12

Effect of the acyl-CoA:cholesterol acyltransferase inhibitor, E5324, on experimental atherosclerosis in rabbits

Hiroshi Tanaka, Issei Ohtsuka, Motoji Kogushi et al. · Atherosclerosis · 1994 · 33 citations

Inflammation, Metabolic Syndrome, Thrombosis +15

Structure-activity relationship of N-[2-(dimethylamino)-6-[3-(5-methyl-4-phenyl-1H-imidazol-1-yl)propoxy]phenyl]-N'-pentylurea and analogs. Novel potent inhibitors of acyl-CoA:cholesterol O-acyltransferase with antiatherosclerotic activity

Teiji Kimura, Yasutaka Takase, Kenji Hayashi et al. · Journal of Medicinal Chemistry · 1993 · 20 citations · Full text